Merck's Remigromig Fails to Show Clear Advantage Over Ranibizumab in DME Trial
Merck's investigational tri-specific antibody, remigromig, has achieved its primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial for adults with diabetic macular edema.
The drug demonstrated non-inferiority compared to ranibizumab, a widely used treatment for this condition. Both the 0.5 mg and 0.8 mg doses of remigromig showed non-inferiority to ranibizumab in measuring best-corrected visual acuity change at week 52.
However, the trial results also showed higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations due to adverse events among patients receiving remigromig compared to those receiving ranibizumab.
The company stated that additional analyses are currently underway to better understand the safety findings from the trial.